ArticleClinical cancer research : an official journal of the American Association for Cancer Research2019
Open access · bronzeAbstract read
In one paragraph
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.
0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed
3.3field-weighted citation impact, top 7% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 74 citations in OpenAlex.
- Identifying Locally Recurrent Versus Second Primary Breast Cancer: Genomic Versus Clinical Criteria from Carolina Breast Cancer Study Phase III.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2026Trial
- The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor-Positive Metastatic Breast Cancer.Cancer discovery · 2020Trial
- ERa-induced mBritish journal of cancer · 2026Article
- FGFR1 Suppresses STING-Mediated Interferon Response in Endocrine Therapy-Resistant Breast Cancer.Cancer research communications · 2026Article
- ExtremeResearch square · 2026Article
- Nuclear FGF2, androgen receptor and Wnt pathway activation define a targetable subset of antiprogestin-resistant luminal breast cancer.British journal of cancer · 2026Article
- Brain FGF2 and NCAM1 contribute to FGFR1-dependent progression of estrogen receptor-positive breast cancer brain metastases.Nature communications · 2026Article
- FGFR4 and HER2 co-expression is associated with the proinflammatory tumor microenvironment in HR + breast cancer.Breast cancer (Tokyo, Japan) · 2026Article
- Lessons from a National Liquid Biopsy Program to Provide Cancer Testing and Treatment for Patients with Advanced Solid Tumors.Current oncology (Toronto, Ont.) · 2025Article
- Clinical benefit of additional whole-exome sequencing over panel sequencing in an all-comer real-world molecular tumor board.ESMO open · 2025Article
- Co-clinical trial targeting ER, FGFR and CDK4/6 in resistant hormone-positive breast cancer with FGFR alterations.NPJ precision oncology · 2025Article
- Review
- FGFR4 in endocrine resistance: overexpression and estrogen regulation without direct causative role.Breast cancer research and treatment · 2025Article
- Selective degradation of FGFR1/2 overcomes antiestrogen resistance in ER+ breast cancer with FGFR1/2 alterations.Cancer letters · 2025Article
- FGFR1 overexpression promotes resistance to PI3K inhibitor alpelisib in luminal breast cancer cells through receptor tyrosine kinase signaling-mediated activation of the estrogen receptor.Cancer drug resistance (Alhambra, Calif.) · 2025Article
- Precision therapeutics and emerging strategies for HR-positive metastatic breast cancer.Nature reviews. Clinical oncology · 2024Review
- FGFR4-driven plasticity in breast cancer progression and resistance to therapy.British journal of cancer · 2024Review
- Overexpression of COL11A1 confers tamoxifen resistance in breast cancer.NPJ breast cancer · 2024Article
- A 50-Year-Old Man Presenting with Multiple Bone Lesions and a Diagnosis of Phosphaturic Mesenchymal Tumor of the Femur.The American journal of case reports · 2024Article
- Therapy for Hormone Receptor-Positive, Human Epidermal Growth Receptor 2-Negative Metastatic Breast Cancer Following Treatment Progression via CDK4/6 Inhibitors: A Literature Review.Breast cancer (Dove Medical Press) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 4 institutions in 1 country.
Joshua Z Drago *Memorial Sloan Kettering Cancer Center, New York City, New York.
Luigi Formisano *Department of Medicine, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee.
Dejan JuricDepartment of Medicine, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts.
Andrzej NiemierkoDepartment of Medicine, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts.
Alberto ServettoSimmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, Texas.
Seth A WanderDepartment of Medicine, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts.
Laura M SpringDepartment of Medicine, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts.
Neelima VidulaDepartment of Medicine, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts.
Jerry YoungerDepartment of Medicine, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts.
Jeffrey PeppercornDepartment of Medicine, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts.
Megan YuenDepartment of Medicine, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts.
Giuliana MalvarosaDepartment of Medicine, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts.
Dennis SgroiDepartment of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
Steven J IsakoffDepartment of Medicine, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts.
Beverly MoyDepartment of Medicine, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts.
Leif W EllisenDepartment of Medicine, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts.
A John IafrateDepartment of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
Carlos L Arteaga *Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, Texas. Bardia.Aditya@mgh.harvard.edu Carlos.Arteaga@UTSouthwestern.edu.
Aditya Bardia *Department of Medicine, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts. Bardia.Aditya@mgh.harvard.edu Carlos.Arteaga@UTSouthwestern.edu.
Massachusetts General Hospital · USSouthwestern Medical Center · USKettering University · USVanderbilt University · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MTISSUE CoreP50CA098131 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI PARK, BEN HO, PIETENPOL, JENNIFER A · 2003 to 2024
$48.7MDana Farber/Harvard Cancer Consortium Career Development Program in Clinical OncologyK12CA087723 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI David Tsai Ting · 2002 to 2026
$17.9MHarvard Clinical and Translational Science CenterKL2TR001100 · NCATS · HARVARD MEDICAL SCHOOL · PI NADLER, LEE MARSHALL · 2013 to 2017
$8.5MNCATS NIH HHS KL2 TR001100NCI NIH HHS K12 CA087723NCI NIH HHS P30 CA008748NCI NIH HHS P50 CA098131
Abstract
purposeWhile
resultsIn the clinical cohort (
conclusionsCollectively, these findings suggest that while
Indexed as
AgedAntineoplastic Agents, HormonalAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsCirculating Tumor DNADrug Resistance, NeoplasmEstrogen Receptor alphaEverolimusFemaleFulvestrantGene AmplificationHumansMechanistic Target of Rapamycin Complex 1Middle AgedNeoplasm MetastasisPiperazinesAntineoplastic Agents, HormonalCirculating Tumor DNAESR1 protein, humanEstrogen Receptor alphaEverolimusFGFR1 protein, humanFulvestrantMechanistic Target of Rapamycin Complex 1MTOR protein, humanpalbociclibPiperazinesProtein Kinase InhibitorsPyridinesReceptor, Fibroblast Growth Factor, Type 1TOR Serine-Threonine KinasesTP53 protein, humanTumor Suppressor Protein p53
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.